Raloxifene Hydrochloride

盐酸雷洛昔芬

Report date: 2026/05/25 20:02:40
NME

Base Information

Drug NameRaloxifene Hydrochloride
Drug Alias Name盐酸雷洛西芬Keoxifene雷洛昔芬CDT-RaloxifeneRaloxifenum +[14] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionEstrogen receptors modulatorsLysine-specific histone demethylase 1 inhibitors
TargetsEstrogen receptorsLysine-specific histone demethylase 1
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)SchizophreniaPsychotic Disorders +[11] 
Global Approved IndicationsOsteoporosis, Postmenopausal
Approved Indications in ChinaOsteoporosis, Postmenopausal
Original Approved Country/TerritoryUnited States
Original Approved Date1997/12/09
Country/TerritoryCzechiaBelgiumCanada +[30] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesEli Lilly And Company
China Registration ClassN/A

Develop Information

Active CompaniesRudolf Magnus Institute – University Of UtrechtDompé farmaceutici SPAEli Lilly Japan Kk +[7] 
Inactive CompaniesEunice Kennedy Shriver National Institute Of Child Health And Human DevelopmentStanford UniversityAddpharma Inc +[7] 
Active IndicationsCoronavirus Disease 2019 (COVID-19)SchizophreniaPsychotic Disorders +[5] 
Inactive IndicationsPelvic PainCardiovascular DiseasesEndometriosis +[6] 

Other Information

ATC CodeG03XC01
Related LinksWikipediaDrugBankKEGG